Team

Meet the passionate minds driving our vision forward.

Core Team Values

These values are the foundation of our teamwork, trust, and integrity—driving
every decision we make and shaping the way we collaborate,
innovate, and grow together.

united by values.

Motivation & Determination – Members of the management team have witnessed firsthand the devastating effects of opioid addiction. The CEO’s stepson has been seriously addicted to opioids for more than 18 years, and other members of the team have friends and family who were addicted and even died from opioid overdoses. The team strongly believes that PPL-103 and PPL-138 can play an important role in addressing the opioid crisis and is determined to get these drugs to market as quickly as possible.
Scientific Knowledge and Creativity – The company’s scientists are highly regarded in their fields. They developed extensive expertise in medicinal chemistry and neuropharmacology at institutions such as Stanford Research Institute (SRI) and Torrey Pines Institute for Molecular Studies. Other prominent scientists at leading institutions have also contributed to the company’s drug development technology.
Scientific Knowledge and Creativity – The company’s scientists are highly regarded in their fields. They developed extensive expertise in medicinal chemistry and neuropharmacology at institutions such as Stanford Research Institute (SRI) and Torrey Pines Institute for Molecular Studies. Other prominent scientists at leading institutions have also contributed to the company’s drug development technology.
Strategic Vision – The team has a clear vision of the company’s business goals and achievable strategies for how to reach them. The primary goal is to advance PPL-103 for acute pain and PPL-138 for chronic pain to Proof of Concept (POC) and then partner with leading pharmaceutical companies to effectively bring them to market worldwide. The secondary goal is to advance compounds for opioid, cocaine and methamphetamine addiction therapy as well as animal health.
Lean Business Practices – The team is experienced in lean business practices. The company has a track record of accomplishing a great deal on a lean budget so far and intends to continue that discipline in the future.

Management & Directors

William Crossman

President & CEO, Serial Entrepreneur - Early Stage Tech.
Bio

john Lawson

Founder, Board Chairman & Chief Scientist Primary Developer of Company’s IP
Contact

LAWRENCE TOLL PH.D.

Chief Neuro-pharmacologist Prof. Florida Atlantic University/ President International Narcotics Research Conference
Contact

TIMMY CHOU

Vice President & CFO CE/CFO for Emerging Companies
Bio

CHRIS TEW

VP & Board Member Sales, Marketing, Business Development Executive
Bio

Scientific Advisors

Daniel E. Levy,
Ph.D.

Lead for Chemical Synthesis & Manufacturing Scale-up

Complete Bio
Timothy P. Bradshaw,
Ph.D.

Consultant, Preclinical and Clinical Trial Planning

Complete Bio
David Heal PhD, DSc, FRSC, HonFBPhS

Consultant, Regulatory Affairs

Complete Bio
Mei-Chuan (Holden) Ko, Ph.D.
Consultant, NHP Studies



Complete Bio
James R Myer.
BS, DABT
Consultant, Tolicology



Complete Bio
Chantal Deziel,
B.Sc, MBA

Consultant, Quality Assurance and Quality Control

Complete Bio
Stephen Husbands, Ph.D.

Consultant, Quality Assurance and Quality Control

Complete Bio
© Copyright 2022 - Phoenix Pharmalabs

Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.

Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.

The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.

Go to Top